Carasent AB (publ)APXZF 80 3-Year ROIIC % is 14.66 as of Dec. 2025, which is 1175% above its 10-year median of 1.15. GuruFocus rates APXZF with a GF Score™ of 80/100 and a GF Value™ of $0.18. The stock has 3 warning signs investors should review. Among 617 Healthcare Providers & Services companies, Carasent AB (publ) ranks better than 69.53% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Carasent AB (publ)'s 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 14.66%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Carasent AB (publ)'s 3-Year ROIIC % or its related term are showing as below:
APXZF's 3-Year ROIIC % is ranked better than 69.53% of 617
companies
in the Healthcare Providers & Services industry
Industry Median: 3.01
vs APXZF: 14.66
Carasent AB (publ) (OTCPK:APXZF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Carasent AB (publ) 3-Year ROIIC % Related Terms
Carasent AB (publ) 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Carasent AB (publ)'s 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
APXZF vs VEEV, BTSG, TEM: 3-Year ROIIC % Comparison
For the Health Information Services subindustry, Carasent AB (publ)'s 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carasent AB (publ) 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Carasent AB (publ)'s 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Carasent AB (publ)'s 3-Year ROIIC % falls into.
Carasent AB (publ)'s 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 1.015 (Dec. 2025) - -0.128842 (Dec. 2022) )
/
( 88.77 (Dec. 2025) - 72.415 (Dec. 2022) )
=
1.143842
/
16.355
=
6.99%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Carasent AB (publ) (APXZF) has a 3-Year ROIIC % of 14.66 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Carasent AB (publ) and its competitors. This is 1175% above median its historical median of 1.15. According to the industry distribution chart, Carasent AB (publ) ranks #188 out of 617 companies in the Healthcare Providers & Services industry, placing it in the top 30.5%.
Is Carasent AB (publ)'s 3-Year ROIIC % too high?
Carasent AB (publ)'s current 3-Year ROIIC % of 14.66 is 1175% above median its 10-year median of 1.15. The Healthcare Providers & Services industry median 3-Year ROIIC % is 3.01. Carasent AB (publ)'s value of 14.66 is 387% above this industry median. Based on the distribution chart, Carasent AB (publ) ranks #188 out of 617 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Carasent AB (publ) has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Carasent AB (publ)'s 3-Year ROIIC % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Carasent AB (publ) ranks #188 out of 617 companies for 3-Year ROIIC %. This puts Carasent AB (publ) in the upper half of its industry. The industry median 3-Year ROIIC % is 3.01. Carasent AB (publ)'s value of 14.66 is 387% above this benchmark. While the company's 10-year median is 1.15 vs. the industry median of 3.01, Carasent AB (publ) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.01, based on 617 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carasent AB (publ)'s current 3-Year ROIIC % of 14.66 is 387% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Carasent AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carasent AB (publ)'s current 3-Year ROIIC % is 14.66, which is 1175% above median its own 10-year median of 1.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carasent AB (publ) stock overvalued right now?
Carasent AB (publ) (APXZF) has a current 3-Year ROIIC % of 14.66. The stock's GF Value™ is $0.18, compared to a current price of $0.15 — trading 16.7% below its estimated fair value. The current 3-Year ROIIC % is 14.66, which is 1175% above median its 10-year median of 1.15 and 387% above the Healthcare Providers & Services industry median of 3.01. Carasent AB (publ)'s overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Carasent AB (publ) (APXZF), the current 3-Year ROIIC % is 14.66 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carasent AB (publ) (APXZF) Overvalued in 2026?
Based on GuruFocus' analysis, Carasent AB (publ) stock appears to be undervalued.
The current stock price of $0.15 is trading 16.7% below its estimated GF Value™ of $0.18.
Key valuation signals for APXZF:
3-Year ROIIC %: 14.66 (1175% above median its 10-year median of 1.15)
GF Value™: $0.18 vs. price of $0.15 (16.7% below fair value)
Industry Position: 387% above the Healthcare Providers & Services median (#188 of 617)
No single metric tells the full story. See the APXZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carasent AB (publ) Formerly Carasent AB is a comprehensive provider of cloudbased EHR solutions and platform services for various organizations within the healthcare sector. With Webdoc as the main product, the group offers a broad ecosystem of services, including solutions for patient communication and business intelligence. Geographically, the company operates in the Nordic region and Germany. It derives maximum revenue from Nordic Region. The solutions provides by the group are: Webdoc; Metodika; Medrave; HPI plustoo; Ad Curis; Ad Opus; Webcur; Data-AL; and Data-Cur.
80GF Score
Get the complete analysis for APXZF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APXZF has been successfully added to your 
